IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with IFN-α is common in classical MPNs, and while it has vanished from the therapeutic landscape of CML treatment with the introduction of TKIs it is now being discussed as a possible add-on therapy.